- Home
- MNRO vs MYGN Comparison
MNRO vs MYGN Comparison
Compare MNRO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNRO | MYGN |
|---|---|---|
| Founded | 1957 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.8M | 625.5M |
| IPO Year | 1991 | 1995 |
Fundamental Metrics
Financial Performance| Metric | MNRO | MYGN |
|---|---|---|
| Price | $21.26 | $6.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $17.67 | $11.82 |
| AVG Volume (30 Days) | 618.4K | ★ 914.9K |
| Earning Date | 01-28-2026 | 02-23-2026 |
| Dividend Yield | ★ 5.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,190,710,000.00 | $825,300,000.00 |
| Revenue This Year | $0.22 | $0.03 |
| Revenue Next Year | $2.75 | $5.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.21 |
| 52 Week Low | $12.20 | $3.76 |
| 52 Week High | $22.62 | $15.47 |
Technical Indicators
Market Signals| Indicator | MNRO | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.54 | 35.26 |
| Support Level | $20.58 | $6.40 |
| Resistance Level | $21.09 | $7.15 |
| Average True Range (ATR) | 0.72 | 0.30 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 94.67 | 16.42 |
Price Performance
Historical ComparisonAbout MNRO Monro Inc.
Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.